Anthera Pharmaceuticals Inc (NASDAQ:ANTH) was the target of a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 2,015,026 shares, a growth of 52.5% from the May 31st total of 1,320,966 shares. Currently, 7.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,232,840 shares, the days-to-cover ratio is currently 1.6 days.
ANTH has been the subject of several research reports. ValuEngine raised Anthera Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Piper Jaffray Companies downgraded Anthera Pharmaceuticals from an “overweight” rating to an “underweight” rating in a research note on Monday, March 12th. Jefferies Financial Group reaffirmed a “hold” rating and set a $0.50 price target on shares of Anthera Pharmaceuticals in a research note on Thursday, March 15th. Zacks Investment Research raised Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.25 price target for the company in a research note on Tuesday, May 1st. Finally, HC Wainwright reissued a “buy” rating on shares of Anthera Pharmaceuticals in a research note on Tuesday, March 6th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. Anthera Pharmaceuticals has an average rating of “Hold” and a consensus target price of $3.44.
A number of hedge funds have recently made changes to their positions in the stock. BVF Inc. IL raised its stake in Anthera Pharmaceuticals by 20.9% in the 4th quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock valued at $2,007,000 after purchasing an additional 209,896 shares during the last quarter. 683 Capital Management LLC acquired a new position in Anthera Pharmaceuticals in the 4th quarter valued at about $399,000. Finally, Armistice Capital LLC acquired a new position in Anthera Pharmaceuticals in the 4th quarter valued at about $1,269,000. 7.49% of the stock is owned by hedge funds and other institutional investors.
Shares of Anthera Pharmaceuticals opened at $0.10 on Friday, MarketBeat reports. Anthera Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $2.97. The stock has a market capitalization of $7.10 million, a P/E ratio of -0.03 and a beta of 2.69.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.